Drug Research
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the Coalition for Epidemic Preparedness Innovations (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI...
Drug Research
Schrodinger Taps Google Clouds High-Performance Compute Solution to Bolster Its Drug Discovery Efforts
Schrödinger, Inc. announced it has entered into a three-year agreement with Google Cloud to substantially increase the speed and capacity of its physics-based computational platform for drug discovery. As part of the agreement, Schrödinger has selected Google Cloud as...
Drug Research
Merck working with EOS AMCM to produce next-generation 3D printed tablets
Merck, a leading science and technology company and AMCM, Starnberg, Germany, announced a cooperation agreement on the 3D printing of tablets. AMCM offers customized additive manufacturing solutions and is a sister company of 3D printing worldmarket leader EOS. The...
Drug Research
Altasciences Adds Comprehensive Contract Manufacturing and Analytical Services to its Early Phase Research Offering
Altasciences, a mid-size CRO specializing in a flexible, innovative approach to providing comprehensive early stage drug development from lead candidate selection to proof of concept, announced that it has acquired Alliance Contract Pharma. This acquisition adds small molecule contract...
Drug Research
Catalent Announces Supplying Blueprint Medicines Precision Therapy AYVAKIT
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene and cell therapies, and consumer health products, welcomes the announcement by Blueprint Medicines Corporation that the U.S. Food and Drug Administration (FDA)...
Drug Research
Novartis and DNDi to jointly develop a new oral drug to treat visceral leishmaniasis
Swiss pharma giant Novartis and non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) have signed a collaboration and license agreement to jointly develop LXE408 for visceral leishmaniasis.
LXE408 is an oral treatment for this parasitic disease, which...
Drug Research
Vir Biotechnology and WuXi Biologics Announce Collaboration for Global Development of Antibodies to Treat COVID-19
Vir Biotechnology, Inc. and WuXi Biologics announced a development and manufacturing collaboration to advance and produce human monoclonal antibodies for the potential treatment of COVID-19 (Coronavirus Disease 2019), a disease caused by SARS-CoV-2.
Under the terms of the agreement, the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
